-
J.P. Morgan Reiterates Human Genome Sciences OW Rating
Wednesday, November 17, 2010 - 10:52am | 104Read More...J.P. Morgan reiterates its OW rating on Human Genome Sciences, Inc. (NASDAQ: HGSI) following the positive FDA panel that overwhelmingly recommended the approval of Benlysta for systemic lupus. “As we had speculated, the drug's safety profile and the disease's unmet medical need ultimately won out...
-
Ford & Human Genome Calls Active (HGSI)
Thursday, November 11, 2010 - 1:47pm | 111Read More...Shares of Ford (NYSE: F) continue to make fresh 52 week highs day after day. New highs have not been made in Ford today though shares are up to 16.58 substantially off the morning low of 16.20. Option traders snapped up the November 17 calls elevating their implied vol 3%. Human Genome Sciences (...
-
Phase 3 Of Epratuzumab Expected To Commence By Year End
Monday, October 18, 2010 - 7:43am | 113Read More...Citigroup has published a research report on Human Genome Sciences (NASDAQ: HGSI) following the company's R&D day held on Friday. In the report, Citigroup writes "On Friday, Immunomedics hosted a R&D day to discuss epratuzumab for lupus. In Ph 2, epratuzumab showed good results. UCB (...
-
HGSI Removed From Citigroup's Top Picks Live! List
Monday, October 11, 2010 - 6:58am | 137Read More...Citigroup has issued a research report on Human Genome Sciences Inc. (NASDAQ: HGSI) upon removing the company from Citi's Top Picks Live! List. In the report, Citigroup writes "We are removing HGS from CIRA's Top Picks Live! List, as the risk/reward profile of the stock has moderated following the...
-
Human Genome Sciences (HGSI) and Novartis (NVS) Hepatitis Treatment Awaits Approval
Wednesday, March 24, 2010 - 8:37am | 132Read More...Biotech company Human Genome Sciences, Inc. (Nasdaq: HGSI) reported that a study has showed that a monthly dose of its drug Zalbin to treat hepatitus C is just as effective as the current weekly treatment. Human Genome Sciences is working with Novartis AG (NYSE: NVS) on the drug, with Novartis AG...
-
J.P. Morgan Maintains Human Genome Sciences (HGSI) Overweight Rating
Wednesday, March 17, 2010 - 9:34am | 203Read More...J.P. Morgan analysts Cory Kasimov and Mona Ashiya reiterated their Overweight rating for shares of Human Genome Sciences, Inc. (Nasdaq: HGSI) The two analysts believed that the failure of a recent Phase 2 non-small cell lung cancer trial would not have a significant impact on Human Genome Sciences...
